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Background
Current HIV-1 integrase inhibitors, such as raltegravir
(MK-518), target the strand transfer activity of the viral
enzyme HIV-1 integrase, which is vital for the HIV-1
replication process and sustained viral infection. Inhibi-
tion of integration by raltegravir is accompanied by an
extremely rapid and strong reduction in viral load. How-
ever, in contrast to prior predictions based on in vitro
experimentation, resistance evolves readily in the clinic,
necessitating the efforts to develop second generation
integrase inhibitors. Against this background we devel-
oped a novel class of INSTIs, the 2-hydroxyisoquinoline-
1,3(2H, 4H)diones (HQDs).
Methods
We have performed detailed analysis of the inhibition of
integration by HQDs. Mechanistic studies (TOA and
QPCR) and combination experiments shed light on the
competiveness of HQDs with known inhibitors of HIV
replication including INSTIs. Cross-resistance profiling,
resistance selection and co-crystallization with the PFV-
intasome allow detailed understanding of the underlying
mechanism of anti-HIV activity.
Results
Biochemical evaluation of HQD demonstrates that this
novel class of catalytic site inhibitors potently blocks
both the 3’ processing and strand transfer reaction of
integrase. TOA and QPCR demonstrate that indeed
HQDs target the integration step of HIV-replication in
cell culture. Interestingly HQDs place the barrier to
resistance very high, resulting in failure to select for
genotypically resistant HIV strains (even after more than
100 passages under selective pressure). A high resolution
(3.4 Å) structure of HDQ bound in the catalytic site of
the PFV-intasome provides evidence for the high barrier
to resistance and allows for structure based optimization
of HQDs’ antiviral activity. Preliminary ADMETox pro-
filing demonstrates that HQDs are associated with low
cellular toxicity.
Conclusion
HQDs are a novel class of integration inhibitors with a
beneficial high barrier to resistance development. The
detailed structural analysis of HQDs bound in the PFV-
intasome active site allows improvement of the antiviral
activity from the sub-micromolar range towards nanomolar
activities which will pave the way for further pre-clinical
development of these novel small molecule catalytic site
inhibitors of HIV-integration.
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